A study of Bortezomib therapy for antibody mediated rejection in kidney transplantatio
Phase 3
- Conditions
- anti-donor HLA antibody positive recipients for kidney transplantation
- Registration Number
- JPRN-UMIN000018628
- Lead Sponsor
- iigata University Medical and Dental Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Cardio-respiratory dysfunction, liver dysfunction (AST/ALT>2.5 times of upper limits), bone marrow dysfunction (neotrophil<1000/ul, platelet<75000), allergy of Bortezomib as well as disqualified recipients with the other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method